Reversing Platinum Resistance in Ovarian Cancer Multicellular Spheroids by Targeting BCL-2

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s187015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Exosomes as Mediators of Platinum Resistance in Ovarian Cancer

Oncotarget
Oncology
2017English

Multimodal Targeting of the BCL-2 Family in Cancer

AACR Education book
2008English

Targeting the BCL-2 Family for Cancer Therapy

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2012English

B7-H3 Induces Ovarian Cancer Drugs Resistance Through an PI3K/AKT/BCL-2 Signaling Pathway

Cancer Management and Research
Oncology
2019English

MicroRNA-138 Promotes Acquired Alkylator Resistance in Glioblastoma by Targeting the BCL-2-Interacting Mediator BIM

Oncotarget
Oncology
2016English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

ABT737 Reverses Cisplatin Resistance by Targeting Glucose Metabolism of Human Ovarian Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2018English

miR-363 Confers Taxane Resistance in Ovarian Cancer by Targeting the Hippo Pathway Member, LATS2

Oncotarget
Oncology
2018English

Increased Expression of Annexin A3 Is a Mechanism of Platinum Resistance in Ovarian Cancer

Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy